Dr. Cindy Xiong is a partner at Foresite Capital. She joined the firm in 2019 and focuses on investment opportunities of private and public biotech companies. Cindy serves(ed) on the boards of Propeller Bio, Chimagen, Raythera, ImmPACT Bio (acquired by Lyell), Remix Therapeutics, and Xinthera (acquired by Gilead). Cindy earned her MBA in Healthcare Management from the Wharton school and started her career in biotech investing at Lilly Asia Ventures and Tybourne Capital. She has over a decade of research experience across academia and industry. Cindy received her PhD in Biology from the University of Michigan and was a Helen Hay Whitney postdoctoral fellow at UCSF.